Persistent Staphylococcus aureus BacteremiaAn Analysis of Risk Factors and Outcomes
Open Access
- 24 September 2007
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 167 (17) , 1861-1867
- https://doi.org/10.1001/archinte.167.17.1861
Abstract
Background Persistent Staphylococcus aureus bacteremia (pSAB) is an emerging problem among hospitalized patients. We studied key clinical characteristics and outcomes associated with pSAB to better define the epidemiological features of this increasingly recognized clinical entity. Methods A retrospective case-control study of patients hospitalized with SAB between January 1, 2001, and September 30, 2004, was conducted to compare the clinical characteristics, management, and outcomes of patients with pSAB (> 7 days of bacteremia) with those of a cohort of patients with nonpersistent SAB (< 3 days of bacteremia). Patients with 4 to 6 days of bacteremia were excluded from the analysis. To detect a potential association between reduced susceptibility to vancomycin and persistent methicillin-resistant SAB, vancomycin susceptibilities were confirmed using standard dilution methods. Results Eighty-four patients with pSAB and 152 patients with nonpersistent SAB were included in the analysis. Methicillin resistance (odds ratio [OR], 5.22; 95% confidence interval [CI], 2.63-10.38), intravascular catheter or other foreign body use (OR, 2.37; 95% CI, 1.11-3.96), chronic renal failure (OR, 2.08; 95% CI, 1.09-3.96), more than 2 sites of infection (OR, 3.31; 95% CI, 1.17-9.38), and infective endocarditis (OR, 10.30; 95% CI, 2.98-35.64) were independently associated with pSAB. The mean time to device removal was significantly longer in patients with pSAB than in patients with nonpersistent SAB (4.94 vs 1.64 days; P < .01). There was no evidence of reduced vancomycin susceptibility among persistent methicillin-resistant S aureus isolates. Clinical outcomes were significantly worse among patients with pSAB. Conclusions Many hospitalized patients may be at risk for pSAB. Aggressive attempts to minimize the risk of complications and poor outcomes associated with pSAB, such as early device removal, should be encouraged.This publication has 13 references indexed in Scilit:
- Management of Persistent Bacteremia Caused by Methicillin‐ResistantStaphylococcus aureus:A Survey of Infectious Diseases ConsultantsClinical Infectious Diseases, 2006
- Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremiaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2006
- Persistence in Staphylococcus aureus bacteremia: Incidence, characteristics of patients and outcomeScandinavian Journal of Infectious Diseases, 2006
- The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemiaScandinavian Journal of Infectious Diseases, 2005
- Health Care–Associated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired InfectionsAnnals of Internal Medicine, 2002
- Laboratory Reporting of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in United States Department of Veterans Affairs Facilities1Emerging Infectious Diseases, 2002
- Proposed Modifications to the Duke Criteria for the Diagnosis of Infective EndocarditisClinical Infectious Diseases, 2000
- Nosocomial and Community-Acquired Staphylococcus aureus Bacteremias from 1980 to 1993: Impact of Intravascular Devices and Methicillin ResistanceClinical Infectious Diseases, 1996
- CDC definitions for nosocomial infections, 1988American Journal of Infection Control, 1988
- Persistent bacteremia in staphylococcal endocarditisThe American Journal of Medicine, 1978